Incyte's good week continues with an encouraging update on IDO1 star epacadostat
Incyte’s complete response rate for a mid-stage combo of its IDO1 drug epacadostat with checkpoint legend Keytruda took a hit in the latest data update, but the growing biotech came away with a thumbs-up from analysts who have been tracking this trial carefully.
Incyte $INCY is steadily beefing up the numbers on their big drug. Going into ESMO next week — where they will add a few more results — researchers reported on 54 patients evaluable for efficacy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.